financetom
Business
financetom
/
Business
/
Kratos Defense & Security Solutions' Fiscal Q1 Adjusted Earnings, Revenue Advance; Fiscal 2024 Revenue Guidance Reiterated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kratos Defense & Security Solutions' Fiscal Q1 Adjusted Earnings, Revenue Advance; Fiscal 2024 Revenue Guidance Reiterated
May 8, 2024 3:59 AM

06:18 AM EDT, 05/08/2024 (MT Newswires) -- Kratos Defense & Security Solutions (KTOS) reported fiscal Q1 adjusted earnings late Tuesday of $0.11 per diluted share, up from $0.06 per share a year earlier.

Analysts surveyed by Capital IQ expected $0.05 earnings per share.

Revenue for the quarter ended March 31 was $277.2 million, up from $231.8 million a year earlier.

Analysts polled by Capital IQ expected $253.9 million.

Kratos said it expects fiscal Q2 revenue of $265 million to $280 million. Analysts polled by Capital IQ are looking for $275.6 million.

Revenue for the current fiscal year is still projected to be $1.13 billion to $1.15 billion, the company said. Analysts surveyed by Capital IQ expect $1.14 billion.

The company's shares were up nearly 2% in recent Wednesday premarket activity.

Price: 19.11, Change: +0.35, Percent Change: +1.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Mar 26, 2024
Monday, Biohaven’s CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company’s experimental obesity drug. Biohaven ( BHVN ) said it is developing an obesity drug that works differently from Novo Nordisk A/S’s and Eli Lilly And Co’s popular GLP-1 drugs. The experimental obesity drug, dubbed taldefgrobep alfa (BHVN-2000), could prevent muscle loss while helping shed weight. The company highlights that 20%-50%...
UK's DS Smith in deal talks with International Paper
UK's DS Smith in deal talks with International Paper
Mar 26, 2024
March 26 (Reuters) - Paper and packaging company DS Smith ( DITHF ) said on Tuesday that it is in discussions with U.S.-listed International Paper ( IP ) regarding a proposal to buy the British packaging firm through a possible all-share offer. Under the terms of the proposal, DS Smith ( DITHF ) shareholders would receive 0.1285 shares in International...
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Mar 26, 2024
01:46 PM EDT, 03/26/2024 (MT Newswires) -- Palisades Goldcorp Ltd. ( PLGDF ) on Tuesday rose 2.2% on last look after reporting that it has secured approval from the TSX Venture Exchange for the company's plan to renew its normal course issuer bid for common shares through the facilities of the TSX-V. Effective April 1, the renewal allows the company...
Spotify Technology Unusual Options Activity
Spotify Technology Unusual Options Activity
Mar 26, 2024
Investors with a lot of money to spend have taken a bullish stance on Spotify Technology ( SPOT ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Copyright 2023-2026 - www.financetom.com All Rights Reserved